South San Francisco biotech Switch Therapeutics unwrapped Tuesday morning with $52 million to finance conditionally activated siRNA molecules.
As its name suggests, the startup said it can switch on the molecules only in selected cells so they’re more precise than other RNAi approaches and can potentially be effective for longer...
